Compare SHEN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | EVO |
|---|---|---|
| Founded | 1902 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.4M | 895.8M |
| IPO Year | 1994 | N/A |
| Metric | SHEN | EVO |
|---|---|---|
| Price | $15.23 | $2.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $26.00 | $7.00 |
| AVG Volume (30 Days) | ★ 186.3K | 91.0K |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $357,854,000.00 | N/A |
| Revenue This Year | $7.12 | $1.29 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $9.67 | $2.31 |
| 52 Week High | $15.92 | $4.80 |
| Indicator | SHEN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 54.48 |
| Support Level | $14.11 | $2.32 |
| Resistance Level | $15.79 | $3.75 |
| Average True Range (ATR) | 0.46 | 0.08 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 70.77 | 90.72 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.